Résumé
Le cancer est la deuxième cause de mortalité chez les femmes de moins de 40 ans en Europe de l’Ouest et aux États-Unis. La survie après cancer s’est nettement améliorée au cours des 30 dernières années. Des avancées majeures ont eu lieu, notamment ces dix dernières années, concernant l’amélioration de la qualité de vie, et particulièrement le développement des techniques de préservation de la fertilité chez les jeunes patientes traitées pour cancer. La chirurgie, la chimiothérapie et la radiothérapie ont des effets délétères variables sur la fertilité féminine. La chirurgie a un impact direct en enlevant l’utérus et les ovaires. La radiothérapie peut affecter les fonctions ovariennes et également la fonction utérine. Les différents agents utilisés en chimiothérapie peuvent agir directement sur la fonction ovarienne. Nous disposons de marqueurs prédictifs des atteintes toxiques potentielles sur les gonades et l’utérus. Différents protocoles de préservation de la fertilité féminine peuvent être proposés, avant la mise en œuvre des traitements anticancéreux ou après le traitement de la tumeur. Cependant, cette prise en charge peut seulement se concevoir si elle n’a aucune conséquence délétère sur la survie des patientes. Outre le problème de la fertilité se pose celui de la contraception, et chez les femmes dont la fonction ovarienne est précocement altérée, celui d’un traitement hormonal substitutif.
Abstract
Cancer is the second cause of death in women under 40 years of age in Western Europe and the United States. Survival after cancer treatment has improved during the past three decades. In line with this, procedures have been developed to optimize the quality of life, in particular the development of fertility-enhancing and fertility-preservation techniques. Surgery, chemotherapy and radiotherapy affect the fertility potential of women in different ways and to different degrees. Surgery has a direct impact by removing the uterus and ovaries. Radiotherapy (external or brachytherapy) may affect ovarian and also uterine function. Different drugs used in chemotherapy may directly influence ovarian function. Some markers have now been evaluated that are predictive of the potential toxic injury to the gonads and uterus. Various procedures could be proposed to preserve fertility potential in women, before delivering anticancer treatments or after treating the tumor. However, such treatments can only be considered if they do not have deleterious consequences on the survival of patients. As well as the preservation of fertility, there is the issue of contraception; and in the case of impaired ovarian function, the issue of a substitute hormonal treatment.
Références
Basille C, Olivennes F, Le Calvez J, et al. (2006) Impact of gonadotropins and steroid hormones on borderline ovarian cells. Hum Reprod 21: 3241–3245
Bath LE, Critchley HO, Chambers SE, et al. (1999) Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol 106: 1265–1272
Bath LE, Wallace WH, Shaw MP, et al. (2003) Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 18: 2368–2374
Benjamin I, Morgan MA, Rubin SC (1999) Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 72: 288–291
Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14(5): 1718–1729
Blumenfeld Z, Eckman A (2005) Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 34: 40–43
Brusamolino E, Lunghi F, Orlandi E, et al. (2000) Treatment of early-stage Hodgkin’s disease with four cycles of ABVD followed by adjuvant radiotherapy: analysis of efficacy and long-term toxicity. Hematologica 85(10): 1032–1039
Callejo J, Salvador C, Miralles A, et al. (2001) Long-term ovarian function evaluation after autografting by transplantation with fresh and frozen-thawed human ovarian tissue. J Clin Endocrinol Metab 86: 4489–4494
Chen SU, Lien YR, Chen HF, et al. (2005) Observational clinical follow-up of oocyte cryopreservation using a slow-freezing method with 1,2-propanediol plus sucrose followed with ICSI. Hum Reprod 20: 1975–1980
Chiarelli AM, Marrett LD, Darlington G (1999) Early menopause and infertility in females after treatment of childhood cancer diagnosed in 1964–1988 in Ontario, Canada. Am J Epidemiol 150: 245–254
Chopin N, et al. (2006) Radical vaginal trachelectomy and laparoscopic pelvic lymphadenectomy: an international series. Int J Gynecol Cancer 16(Suppl 3): 602
Cohen J, Simons RF, Edwards RG, et al. (1985) Pregnancies following the frozen storage of expanding human blastocysts. J In Vitro Fertil Embryo Transf 2: 59–64
Creus M, Peñarrubia J, Fábregues F, et al. (2000) Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. Hum Reprod 15: 2341–2346
Critchley HO, Wallace WH (2005) Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 34: 64–68
Demeestere I, Simon P, Emiliani S, et al. (2007) Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin’s disease. Oncologist 12(12): 1437–1442
Donnez J, Dolmans MM, Demylle D, et al. (2004) Live birth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364: 1405–1410
Elis A, Tevet A, Yerushalmi R, et al. (2006) Fertility status among women treated for aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 47: 623–627
Faddy MJ, Gosden RG, Gougeon A, et al. (1992) Accelerated disappearance of ovarian follicles in the mid-life: implications for forecasting menopause. Hum Reprod 7: 1342–1346
Fanchin R, Taieb J, Lozano DH et al. (2005) High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 20: 923–927
Fisher B, Cheung AY (1984) Delayed effect of radiation therapy with or without chemotherapy on ovarian function in women with Hodgkin’s disease. Acta Radiol Oncol 23: 43–48
Fortin A, Morice P, Thoury A et al. (2007) Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril 87: 591–596
Franchi-Rezgui P, Rousselot P, Espié M, et al. (2003) Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. Hematol J 4: 116–120
Gershenson DM (1988) Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 6(2): 270–275
Haie-Meder C, et al. (2004) Consequences of brachytherapy on uterine myocontractility. Radiother Oncol 71: S54
Haie-Meder C, Mlika-Cabanne N, Michel G, et al. (1993) Radiotherapy after ovarian transposition: ovarian function and fertility preservation. Int J Radiol Oncol Biol Physics 25: 419–424
Holm K, Nysom K, Brocks V, et al. (1999) Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogenic bone marrow transplantation. Bone Marrow transplant 23: 359–363
Jemal A, Siegel R, Ward E, et al. (2006) Cancer statistics. CA Cancer J Clin 56: 106–130
Jones AL (2006) Fertility and pregnancy after breast cancer. Breast 15(Suppl 2): S41–S46
Larsen EC, Müller J, Schmiegelow K, et al. (2003) Reduced ovarian function in long-term survivors of radiation-and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 88: 5307–5314
Lassalle B, Testart J, Renard JP (1985) Human embryo features that influence the success of cryopreservation with the use of 1,2 propanediol. Fertil Steril 44: 645–651
Lee SJ, Schover LR, Partridge AH, et al. (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24: 2917–2931
Lobo R (2005) Potential options for preservation of fertility in women. N Engl J Med 353: 64–73
Lower EE, Blau R, Gazder P, Tummala R (1999) The risk of premature menopause induced by chemotherapy for early breast cancer. J Women’s Health Gend Based Med 8(7): 949–954
Lushbaugh CC, Casarett GW (1976) The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 37(2 Suppl): 1111–1125
Meirow D, Nugent D (2001) The effect of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7: 535–543
Meirow D, Levron J, Eldar-Geva T, et al. (2005) Pregnancy after transplantation of cryopreserved ovarian tissue in patient with ovarian failure after chemotherapy. N Engl J Med 353: 318–321
Morice P (2006) Borderline tumor of the ovary and fertility. Eur J Cancer 42: 149–158
Morice P, Juncker L Rey A, et al. (2000) Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril 74: 743–748
Morice P, Leblanc E, Rey A, et al. (2005) Conservative treatment of epithelial ovarian Cancer: Results of a French multicenter study of the GCCLCC (Groupe des chirurgiens de centres de lutte contre le cancer) and SFOG (Société française d’oncologie gynécologique). Human Reprod 20: 1379–1385
Oktay K, Buyuk E, Veeck L, et al. (2004) Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 363: 837–840
Oktay K, Hourvitz A, Sahin G, et al. (2006) Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. JCEM 91: 3885–3890
Pereyra Pacheco B, Méndez Ribas JM, Milone G, et al. (2001) Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 81: 391–397
Porcu E, Fabbri R, Damiano G, et al. (2000) Clinical experience and applications of oocyte cryopreservation. Mol. Cell Endocrinol 169: 33–37
Reh A, Oktem O, Oktay K (2007) Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril Dec 29 [Epub ahead of print]
Roberts JE and Oktay K (2005) Fertility preservation: a comprehensive approach to the young woman with cancer. J Natl Cancer Inst Monogr 34: 57–59
Santoro A, Bredenfeld H, Devizzi L et al. (2000) Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 18: 2615–2619
Sklar CA, Mertens AC, Mitby P, et al. (2006) Premature menopause in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Nat Clin Invest 98: 890–896
Stehlik E, Stehlik J, Katayama KP, et al (2005) Vitrification demonstrates significant improvement versus slow freezing of human blastocysts. Reprod Biomed Online 11: 53–57
Stillman RJ, Schinfeld JS, Schiff I, et al., (1981) Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol 139(1): 62–66
Weenen C, Laven JS, Von Bergh AR, et al. (2004) Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10: 77–83
Yamamoto R, Okamoto K, Yukiharu T, et al. (2001) A study of risk factor for ovarian metastases in stage IB-IIB cervical carcinoma and analysis of ovarian function after a transposition. Gynecol Oncol 82: 312–316
Yoon TK, Kim TJ, Park SE, et al. (2003) Live births after vitrification of oocytes in a stimulated in vitro fertilization-embryo transfer program. Fertil Steril 79: 1323–1326
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Lévy, R., Frydman, N., Filali, M. et al. Perturbations hormonales, fertilité et contraception après le traitement d’un cancer. Oncologie 10, 254–262 (2008). https://doi.org/10.1007/s10269-008-0860-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-008-0860-0